| UHC Commercial Medical & Drug | Clotting Factors, Coagulant Blood Products, & Other Hemostatics – Commercial Medical Benefit Drug Policy | 2026-10-01 |
| UHC Commercial Medical & Drug | Diagnostic Dynamic Spinal Visualization and Vertebral Motion Analysis – Commercial and Individual Exchange Medical Policy | 2026-10-01 |
| UHC Commercial Medical & Drug | Electrical Stimulation for the Treatment of Pain and Muscle Rehabilitation – Commercial and Individual Exchange Medical Policy | 2026-10-01 |
| UHC Commercial Medical & Drug | Extracorporeal Shock Wave Therapy (ESWT) for Musculoskeletal Conditions and Soft Tissue Indications – Commercial and Individual Exchange Medical Policy | 2026-10-01 |
| UHC Commercial Medical & Drug | Gender Dysphoria Treatment – Commercial and Individual Exchange Medical Policy | 2026-10-01 |
| UHC Commercial Medical & Drug | Genetic Testing for Hereditary Cancer – Commercial and Individual Exchange Medical Policy | 2026-10-01 |
| UHC Commercial Medical & Drug | Immune Globulin (IVIG and SCIG) – Commercial Medical Benefit Drug Policy | 2026-10-01 |
| UHC Commercial Medical & Drug | Injectable Dermal Fillers and Bulking Agents – Commercial and Individual Exchange Medical Policy | 2026-10-01 |
| UHC Commercial Medical & Drug | Lower Extremity Endovascular Procedures – Commercial and Individual Exchange Medical Policy | 2026-10-01 |
| UHC Commercial Medical & Drug | Medical Benefit Therapeutic Equivalent Medications – Excluded Drugs – Commercial Medical Benefit Drug Policy | 2026-10-01 |